Andra AP fonden Sells 5,000 Shares of Zoetis Inc. (ZTS)
Andra AP fonden lowered its stake in Zoetis Inc. (NYSE:ZTS) by 5.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 92,300 shares of the company’s stock after selling 5,000 shares during the period. Andra AP fonden’s holdings in Zoetis were worth $5,758,000 as of its most recent filing with the SEC.
A number of other large investors have also made changes to their positions in ZTS. Penserra Capital Management LLC increased its stake in shares of Zoetis by 13.0% in the second quarter. Penserra Capital Management LLC now owns 3,380 shares of the company’s stock valued at $210,000 after buying an additional 390 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of Zoetis by 50.2% in the second quarter. Prudential Financial Inc. now owns 2,406,563 shares of the company’s stock valued at $150,122,000 after buying an additional 803,980 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of Zoetis by 41.1% in the second quarter. Parallel Advisors LLC now owns 2,263 shares of the company’s stock valued at $141,000 after buying an additional 659 shares during the last quarter. Mastrapasqua Asset Management Inc. acquired a new stake in shares of Zoetis during the second quarter valued at $4,711,000. Finally, Schaper Benz & Wise Investment Counsel Inc. WI acquired a new stake in shares of Zoetis during the second quarter valued at $393,000. 93.31% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Zoetis Inc. (NYSE ZTS) opened at 61.33 on Monday. Zoetis Inc. has a 12 month low of $46.86 and a 12 month high of $63.85. The stock has a market capitalization of $30.00 billion, a P/E ratio of 34.67 and a beta of 1.02. The firm has a 50 day moving average of $61.83 and a 200-day moving average of $58.45.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting analysts’ consensus estimates of $0.53. The business had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. Zoetis’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.49 earnings per share. Analysts forecast that Zoetis Inc. will post $2.34 earnings per share for the current year.
WARNING: “Andra AP fonden Sells 5,000 Shares of Zoetis Inc. (ZTS)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://theolympiareport.com/2017/08/28/andra-ap-fonden-sells-5000-shares-of-zoetis-inc-zts.html.
Several equities research analysts recently weighed in on the stock. Piper Jaffray Companies set a $73.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Thursday. Cantor Fitzgerald set a $75.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, August 14th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $62.00 target price on shares of Zoetis in a research note on Monday, August 7th. Finally, Deutsche Bank AG downgraded shares of Zoetis from a “buy” rating to a “hold” rating and set a $65.00 target price on the stock. in a research note on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have given a buy rating to the company’s stock. Zoetis presently has a consensus rating of “Buy” and an average price target of $65.44.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.